Pulmonary Complications of Biological Therapies in Children and Adults with Rheumatic Diseases

http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm105782.htm (last accessed 9 December 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 (last accessed 9 December 2012). Keystone, 2005, Safety of biologic therapies- an update, J Rheumatol, 32, 8, 10.1093/rheumatology/keh617 Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 Nisar, 2011, The Role of Tumour Necrosis Factor-α in the Treatment of Rheumatoid Arthritis- A Review, European Musculoskeletal Review, 6, 174 Cush JJ, Kay J, Dao H. Drug Safety Quarterly- an online publication of ACR Drug safety committee. 2012;4:1–4. Galloway JB, Hyrich KL, Mercer LK et al, BSRBR Control Centre Consortium, Deborah P. M. Symmons, and on behalf of the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50:124–131. Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2, CD008794 Gardam, 2003, Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, Lancet Infect Dis, 3, 148, 10.1016/S1473-3099(03)00545-0 BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment British Thoracic Society Standards of Care Committee. Thorax 2005;60:800–805. (available online at http://www.britthoracic.org.uk/Portals/0/Clinical%20Information/Tuberculosis/Guidelines/antitnf.pdf). Beukelman T, Patkar MN, Saag KG et al., 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res. 2011;63:465–82. (http://www.rheumatology.org/practice/clinical/guidelines/ACR_2011_jia_full_manuscript.pdf). Hyrich, 2004, Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety, Ann Rheum Dis, 63, 1538, 10.1136/ard.2004.024737 Peno-Green, 2002, Lung injury linked to etanercept therapy, Chest, 122, 1858, 10.1378/chest.122.5.1858 Ostor, 2004, Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab, BMJ, 329, 1266, 10.1136/bmj.329.7477.1266 Ostor, 2006, Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis, J Rheumatol, 33, 622 Perez-Alvarez, 2011, Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases, Sem Arthritis Rheum, 41, 256, 10.1016/j.semarthrit.2010.11.002 Hadjinicolaou, 2011, Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review, Rheumatology (Oxford), 50, 2297, 10.1093/rheumatology/ker289 Pearce, 2012, Interstitial lung disease following certolizumab pegol, Rheumatology (Oxford), 51, 578, 10.1093/rheumatology/ker309 Millar, 2012, Fatal fibrosing alveolitis with certolizumab, Rheumatology (Oxford), 51, 953, 10.1093/rheumatology/ker452 Dixon, W., Hyrich, K., Watson, K., Lunt, M., BSRBR_Control_Centre_Consortium, B. & Symmons, D. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086–1091. Czuczman, 2010, The future of CD20 monoclonal antibody therapy in B-cell malignancies, Leuk Lymphoma, 51, 983, 10.3109/10428191003717746 Cohen, 2006, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks, Arthritis Rheum, 54, 2793, 10.1002/art.22025 Genentech. Rituxan: highlights of prescribing information (revised), 2008, http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf (12 Dec 2012, date last accessed). Hadjinicoloau, 2012, Non infectious pulmonary toxicity of Rituximab: a systematic review, Rheumatology (Oxford), 51, 653, 10.1093/rheumatology/ker290 N ICE. TAG 238 http://www.nice.org.uk/nicemedia/live/13627/57489/57489.pdf Nisar, 2012, The role of Tocilizumab monotherapy in the management of rheumatoid arthritis: a review, Int J Clin Rheumatol, 7, 9, 10.2217/ijr.11.66 Yokota, 2008, Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials, Arthritis Rheum, 58, S631 Khraishi, 2010, Safety profile of abatacept in rheumatoid arthritis- a review, Clin Ther, 32, 1855, 10.1016/j.clinthera.2010.10.011 Ruperto, 2008, Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, Lancet, 372, 383, 10.1016/S0140-6736(08)60998-8 Ilowite, 2009, Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study, Clin Rheumatol, 28, 129, 10.1007/s10067-008-0995-9 Quartier, 2011, A multicentre, randomised, double-blind, placebo-controlled trial with the IL-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), Ann Rheum Dis, 70, 747, 10.1136/ard.2010.134254 Lovell, 2009, Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA), Arthritis Rheum, 60, S768 Falagas, 2007, Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review, Clin Rheumatol, 26, 663, 10.1007/s10067-006-0441-9 Lee, 2005, Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease, Chest, 127, 2019, 10.1378/chest.127.6.2019 Olson, 2011, Rheumatoid arthritis-interstitial lung disease-associated mortality, Am J Respir Crit Care Med, 183, 372, 10.1164/rccm.201004-0622OC Quezada, 2012, Lung involvement in rheumatologic diseases in children, Allergol Immunopathol (Madrid), 40, 88, 10.1016/j.aller.2011.02.009 Alkady, 2012, Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis, Rheumatol Int, 32, 39, 10.1007/s00296-010-1548-5 Chatterjee, 2004, Severe interstitial pneumonitis associated with infliximab therapy, Scand J Rheumatol, 33, 276, 10.1080/03009740410005836 Siwik, 2000, Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro, Circ Res, 86, 1259, 10.1161/01.RES.86.12.1259 Sullivan, 2005, Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway, Am J Respir Cell Mol Biol, 32, 342, 10.1165/rcmb.2004-0288OC Piguet, 1994, Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice, Eur Respir J, 7, 515, 10.1183/09031936.94.07030515 Strieter, 2005, Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel, Chest, 128, 10.1378/chest.128.5_suppl_1.526S Belperio, 2002, Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients, Transplantation, 73, 591, 10.1097/00007890-200202270-00020